Publication | Closed Access

Optimization of Hyperthermic Intraperitoneal Chemotherapy With Oxaliplatin Plus Irinotecan at 43°C After Compete Cytoreductive Surgery: Mortality and Morbidity in 106 Consecutive Patients

Consecutive PatientsSurgical OncologyCompete Cytoreductive SurgeryMedicineMetronomic TherapySurgeryMetronomic ChemotherapyCancer TreatmentOncologyRadiation OncologyCancer ResearchHyperthermic Intraperitoneal Chemotherapy